It can present while acute or chronic liver disease, early or late throughout therapy . The chance increases with higher dosages and longer durations of therapy. The indication for amiodarone should be reviewed and other agents considered. Monitoring of liver function assessments is recommended through the entire period of amiodarone therapy and for 12 months beyond cessation.e. Is above about 150 U/L).. Amiodarone hepatoxicity Liver and lung toxicity associated with the usage of amiodarone is uncommon but potentially life-threatening. Hepatotoxicity may be reversible if the medication is ceased the moment toxicity is suspected.We constantly see post-BCT patients get an IM in fact it is always normal, Scott Herbert, MD, senior author of the scholarly study and a scientific associate professor of radiation oncology at Drexel University in Philadelphia, said. I think this will prompt doctors to reconsider the recommendation for an IM, that will save the medical community and the patients money ultimately, in addition to decreasing patient stress and minimizing needless biopsies.